When Mark Zuckerberg and Priscilla Chan proposed curing all disease, top scientists didn't cite scientific limits. Instead, they pointed to operational failures: data silos, unpublished information, and non-scalable tools. This revealed the core problem was engineering and infrastructure, not just pure science.

Nonprofits occupy a unique space. While academia pursues discovery and industry seeks revenue, nonprofits can fund "infrastructure" projects like large, open-access datasets. These efforts accelerate the entire ecosystem, a goal neither academia nor industry is incentivized to pursue alone.

CZI focuses on creating new tools for science, a 10-15 year process that's often underfunded. Instead of just giving grants, they build and operate their own institutes, physically co-locating scientists and engineers to accelerate breakthroughs in areas traditional funding misses.

The shift to a nonprofit was a strategic decision to create an incentive structure that prioritizes maximizing educational impact over profit. This move prevents future leaders from pivoting to more lucrative but less mission-aligned business models like freemium services or selling to EdTech companies.

Unlike publicly traded competitors, Servier's non-profit foundation ownership insulates it from short-term investor pressures. This freedom enables a long-term strategic focus, allowing the company to pursue high-risk, scientifically complex areas like rare oncology that public companies often cannot justify to shareholders.

OpenAI's non-profit parent retains a 26% stake (worth $130B) in its for-profit arm. This novel structure allows the organization to leverage commercial success to generate massive, long-term funding for its original, non-commercial mission, creating a powerful, self-sustaining philanthropic engine.

Instead of funding small, incremental research grants, CZI's philanthropic strategy focuses on developing expensive, long-term tools like AI models and imaging platforms. This provides leverage to the entire scientific community, accelerating the pace of the whole field.

CZI strategically focuses on developing long-term scientific tools and platforms by operating its own labs. This addresses a funding gap left by government grants for individual investigators and public-health-focused philanthropies, aiming to accelerate research for all scientists.

Priscilla Chan argues that a for-profit model naturally focuses on common diseases, leaving a long tail of rare conditions "orphaned." By providing general-purpose, open-source tools, Biohub decentralizes research, enabling scientists passionate about a specific rare disease to make progress that would otherwise be economically unviable.